CIELO: a randomized, double-blind, placebo-controlled, phase 3 basket study of satralizumab in patients with NMDAR- or LGI1-antibody encephalitis
Hauptverfasser: | Gelfand, JM, Abboud, H, Irani, SR, Nakajima, H, Piquet, A, Pittock, SJ, Yeh, EA, Overell, J, Rajan, S, El-Khairi, M, Lee, S-T |
---|---|
Format: | Conference item |
Sprache: | English |
Veröffentlicht: |
Wiley
2022
|
Ähnliche Einträge
Ähnliche Einträge
-
Innovation and optimization in autoimmune encephalitis trials: the design and rationale for the Phase 3, randomized study of satralizumab in patients with NMDAR-IgG-antibody-positive or LGI1-IgG-antibody-positive autoimmune encephalitis (CIELO)
von: Lee, S, et al.
Veröffentlicht: (2024) -
Innovation and optimization in autoimmune encephalitis trials: the design and rationale for the Phase 3, randomized study of satralizumab in patients with NMDAR-IgG-antibody-positive or LGI1-IgG-antibody-positive autoimmune encephalitis (CIELO)
von: Soon-Tae Lee, et al.
Veröffentlicht: (2024-08-01) -
CSF Findings in Chinese Patients with NMDAR, LGI1 and GABABR Antibody-Associated Encephalitis
von: Qiao S, et al.
Veröffentlicht: (2024-03-01) -
Comprehensive B-Cell Immune Repertoire Analysis of Anti-NMDAR Encephalitis and Anti-LGI1 Encephalitis
von: Jingjing Feng, et al.
Veröffentlicht: (2021-10-01) -
Seizures and risk of epilepsy in anti‐NMDAR, anti‐LGI1, and anti‐GABABR encephalitis
von: Chun‐Hong Shen, et al.
Veröffentlicht: (2020-08-01)